Literature DB >> 14734438

Adverse effects of antiretroviral therapy for HIV infection.

Valentina Montessori1, Natasha Press, Marianne Harris, Linda Akagi, Julio S G Montaner.   

Abstract

Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in CD4 T cell counts is associated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to patient. A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734438      PMCID: PMC315530     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  70 in total

1.  Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis.

Authors:  K Brinkman; S Vrouenraets; R Kauffmann; H Weigel; J Frissen
Journal:  AIDS       Date:  2000-12-01       Impact factor: 4.177

2.  Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.

Authors:  M den Brinker; F W Wit; P M Wertheim-van Dillen; S Jurriaans; J Weel; R van Leeuwen; N G Pakker; P Reiss; S A Danner; G J Weverling; J M Lange
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

3.  Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors.

Authors:  K A Hollmig; S B Beck; D C Doll
Journal:  Eur J Med Res       Date:  2001-03-26       Impact factor: 2.175

4.  Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.

Authors:  M John; C B Moore; I R James; D Nolan; R P Upton; E J McKinnon; S A Mallal
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

5.  Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-01-05       Impact factor: 17.586

6.  Respiratory failure associated with the lipodystrophy syndrome in an HIV-positive patient with compromised lung function.

Authors:  N Press; V Montessori; T R Bai; J Montaner
Journal:  Can Respir J       Date:  2001 Jul-Aug       Impact factor: 2.409

7.  Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.

Authors:  Y Benhamou; V Di Martino; M Bochet; G Colombet; V Thibault; A Liou; C Katlama; T Poynard
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

Review 8.  Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac.

Authors:  S Kodoth; S Bakshi; P Scimeca; K Black; S Pahwa
Journal:  AIDS Patient Care STDS       Date:  2001-07       Impact factor: 5.078

9.  Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study.

Authors:  A Schwenk; J P Breuer; G Kremer; K Römer; U Bethe; C Franzen; G Fätkenheuer; B Salzberger
Journal:  Eur J Med Res       Date:  2000-10-30       Impact factor: 2.175

10.  Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.

Authors:  M P Dubé; D Sprecher; W K Henry; J A Aberg; F J Torriani; H N Hodis; J Schouten; J Levin; G Myers; R Zackin; T Nevin; J S Currier
Journal:  Clin Infect Dis       Date:  2000-11-07       Impact factor: 9.079

View more
  104 in total

1.  Psychometric evaluation of the functional assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials.

Authors:  Muriel Viala-Danten; Dominique Dubois; Hélène Gilet; Silas Martin; Katrien Peeters; David Cella
Journal:  Qual Life Res       Date:  2010-05-28       Impact factor: 4.147

2.  An exploration of Prevotella-rich microbiomes in HIV and men who have sex with men.

Authors:  Abigail J S Armstrong; Michael Shaffer; Nichole M Nusbacher; Christine Griesmer; Suzanne Fiorillo; Jennifer M Schneider; C Preston Neff; Sam X Li; Andrew P Fontenot; Thomas Campbell; Brent E Palmer; Catherine A Lozupone
Journal:  Microbiome       Date:  2018-11-05       Impact factor: 14.650

Review 3.  Economic models of antiretroviral therapy: searching for the optimal strategy.

Authors:  Fred J Hellinger
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.

Authors:  Zachariah Dorey-Stein; Valerianna K Amorosa; Jay R Kostman; Vincent Lo Re; Richard P Shannon
Journal:  J Cardiometab Syndr       Date:  2008

5.  Resistance evolution in HIV - modeling when to intervene.

Authors:  Liliana Mabel Peinado Cortes; Ryan Zurakowski
Journal:  Proc Am Control Conf       Date:  2012

6.  A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Authors:  Matt S Anderson; Sauzanne Khalilieh; Ka Lai Yee; Rachael Liu; Li Fan; Matthew L Rizk; Vedangi Shah; Azra Hussaini; Ivy Song; Lisa L Ross; Joan R Butterton
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

7.  A computational model of mitochondrial AZT metabolism.

Authors:  Patrick C Bradshaw; Jiaxin Li; David C Samuels
Journal:  Biochem J       Date:  2005-12-01       Impact factor: 3.857

8.  Safety of Bariatric Surgery in Morbidly Obese Patients with Human Immunodeficiency Virus: A Nationwide Inpatient Sample Analysis, 2004-2014.

Authors:  Thomas R McCarty; Prabin Sharma; Andrew Lange; Julius N Ngu; Ashley Davis; Basile Njei
Journal:  Bariatr Surg Pract Patient Care       Date:  2020-09-14       Impact factor: 0.607

9.  Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report.

Authors:  Antonio Di Biagio; Raffaella Rosso; Patrizia Monteforte; Rodolfo Russo; Guido Rovetta; Claudio Viscoli
Journal:  J Med Case Rep       Date:  2009-07-22

10.  Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

Authors:  Kavya Ramkumar; Nouri Neamati
Journal:  Core Evid       Date:  2010-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.